The Alliance of Community Health Plans (ACHP) sent a letter to key Congressional committee leaders urging hearings on the high-cost cell and gene therapies rapidly gaining FDA approval. ACHP recognizes that these new treatments will require changes to how we think about coverage and payment and calls on Congress to engage to balance the need for patient access with the high up-front prices of these therapies.
New from ACHP:
- ACHP Responds to RFI on the State of Artificial Intelligence in Health Care
- ACHP Urges HHS to Take Action to Prevent Future Cyberattacks
- Frequently Asked Questions on Broker Compensation Reform
- “Overcoming Barriers: Transforming Black Maternal Health Through Research” Webinar
- PODCAST: ACHP’s Ceci Connolly Joins Managed Healthcare Executive DC Roundtable Podcast
- OP-ED: What Could We Do if GLP-1 Weight Loss Drugs Were Free? Would Our Obesity Epidemic Be Solved for Good?